Non-alcoholic fatty liver in hereditary fructose intolerance

This multicenter cross-sectional study evaluates the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with hereditary fructose intolerance (HFI) under adequate dietary treatment. Sixteen genetically confirmed patients were assessed through anthropometric measurements, biochemical...

Descripción completa

Detalles Bibliográficos
Autores: Aldamiz Echevarría, Luis, Heras, Javier de las, Couce, María Luz, Alcalde, Carlos, Vitoria, Isidro, Bueno, María, Blasco, Javier, García, María Concepción, Ruiz, Mónica, Suárez del Villar, Rafael, Andrade, Fernando, Villate, Olatz
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad Camilo José Cela (UCJC)
Repositorio:Depósito Digital e-UCJC
OAI Identifier:oai:repositorio.ucjc.edu:20.500.12020/1931
Acceso en línea:http://hdl.handle.net/20.500.12020/1931
https://doi.org/10.1016/j.clnu.2019.02.019
Access Level:acceso abierto
Palabra clave:Ciencias Biomédicas
Ciencias de la Naturaleza
Non-alcoholic fatty liver disease
Hereditary fructose intolerance
ALDOB gene
Fatty liver
Metabolic disorders
Genetic mutations
3205 Medicina Interna
3206 Ciencias de la Nutrición
3207 Patología
2409 Genética
Descripción
Sumario:This multicenter cross-sectional study evaluates the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with hereditary fructose intolerance (HFI) under adequate dietary treatment. Sixteen genetically confirmed patients were assessed through anthropometric measurements, biochemical profiling, genetic analysis of ALDOB mutations, and imaging techniques including ultrasound and hepatic MRI. NAFLD was identified in 56% of patients, without association with obesity or insulin resistance. A significant correlation was observed between the c.448G>C (p.Ala150Pro) mutation and the presence of hepatic steatosis. These findings suggest that NAFLD may represent part of the phenotypic spectrum of treated HFI rather than being exclusively linked to poor metabolic control. The study contributes to improving long-term clinical monitoring strategies in rare metabolic disorders.